Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 6/20 | 0.60 |
| ▸ | ADRB1 | P08588 | 5/20 | 0.51 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.51 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.49 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.49 |
| ▸ | HTR1A | P08908 | 5/20 | 0.49 |
| ▸ | HTR6 | P50406 | 5/20 | 0.49 |
| ▸ | HTR7 | P34969 | 4/20 | 0.49 |
| ▸ | HTR3A | P46098 | 4/20 | 0.49 |
| ▸ | HTR2A | P28223 | 4/20 | 0.49 |
| ▸ | HTR1D | P28221 | 4/20 | 0.49 |
| ▸ | HTR1B | P28222 | 3/20 | 0.49 |
| ▸ | HTR5A | P47898 | 2/20 | 0.49 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.49 |
| ▸ | HTR3B | O95264 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | MTOR | P42345 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL430546 | 0.95 | NCF1 (0.56) | NCF1ADRB1ADRB2HTR1AHTR6 | |
| SCHEMBL4176462 | 0.83 | NCF1 (0.72) | NCF1ADRB1ADRB2HTR1AHTR6 | |
| SCHEMBL4175589 | 0.80 | PIM2 (0.41) | NCF1ADRB1ADRB2HTR1AHTR6 | |
| SCHEMBL428165 | 0.76 | NCF1 (0.69) | NCF1ADRB1ADRB2HTR1AHTR6 | |
| SCHEMBL7719591 | 0.74 | HTR6 (0.87) | NCF1ADRB1ADRB2HTR1AHTR6 | |
| SCHEMBL23412205 | 0.72 | NCF1 (0.88) | NCF1ADRB1ADRB2CHRNB2CHRNA4 | |
| SCHEMBL1537943 | 0.72 | NCF1 (0.48) | NCF1ADRB1ADRB2CHRNB2CHRNA4 | |
| SCHEMBL9310335 | 0.71 | ADRB1 (0.87) | NCF1ADRB1HTR1AHTR6HTR7 | |
| SCHEMBL27656377 | 0.71 | NCF1 (0.55) | NCF1ADRB1ADRB2HTR1AHTR6 | |
| SCHEMBL409069 | 0.70 | ADRB1 (0.86) | NCF1ADRB1HTR1AHTR6HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090076274-A1 | BENZOXAZINONE DERIVATIVES, PREPARATION THEREOF AND USES IN THE TREATMENT OF CNS AND OTHER DISORDERS | GLAXO GROUP LIMITED | 2009-03-19 | — | — | US | disclosed |
| US-20060264429-A1 | Benzoxazinone derivatives, preparation thereof and uses in the treatment of cns and other disorders | GLAXO GROUP LIMITED (GB) | 2006-11-23 | — | — | US | disclosed |
| EP-1562917-A1 | BENZOXAZINONE DERIVATIVES, PREPARATION THEREOF AND USES IN THE TREATMENT OF CNS AND OTHER DISORDERS | GLAXO GROUP LIMITED (GB) | 2005-08-17 | — | — | EP | disclosed |
| WO-2004046124-A1 | BENZOXAZINONE DERIVATIVES, PREPARATION THEREOF AND USES IN THE TREATMENT OF CNS AND OTHER DISORDERS | GLAXO GROUP LIMITED (GB) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264429-A1 | Benzoxazinone derivatives, preparation thereof and uses in the treatment of cns and other disorders | XDH, CYP4X1, PDHX | NCF1 3910/4885ADRB1 359/4885ADRB2 456/4885 |
| US-20090076274-A1 | BENZOXAZINONE DERIVATIVES, PREPARATION THEREOF AND USES IN THE TREATMENT OF CNS AND OTHER DISORDERS | XDH, CYP4X1, PDHX | NCF1 3681/4885ADRB1 1042/4885ADRB2 1020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.